We describe the activities of RX-P763, RX-P766, RX-P770, RX-P792, RX-P793, and RX-P808 against strains of resistant Pseudomonas aeruginosa. These compounds target the large subunit of the bacterial ribosome and have broad-spectrum activities against multidrug-resistant pathogens. All compounds demonstrated in vitro activity against P. aeruginosa, with MIC 90 values of 4 to 8 g/ml (range, 0.5 to 64). These novel compounds had narrow MIC distributions and maintained activity despite resistance phenotypes to other commonly utilized agents.
MICs were determined in duplicate with the reference Clinical and Laboratory Standards Institute broth microdilution method (3) . MICs for the antimicrobials imipenem, meropenem, piperacillin-tazobactam, cefepime, ceftazidime, ciprofloxacin, levofloxacin, and tobramycin were also determined by broth microdilution. P. aeruginosa ATCC 27853 was used as the quality control organism for all six novel compounds. Acceptable ranges for all six compounds were 2 to 8 g/ml. Of the 200 isolates, 67% were R-TZP, 42% were R-TAZ and R-IMI, 32% were R-CIPRO, and 21% were R-TOB. Further, 21% were considered MDR, with resistance to 3 or more drug classes.
The MIC distributions of all six compounds are shown in Fig.  2 . The MIC profiles of each of the six novel compounds were narrow, and modal MICs of 2 g/ml were observed for all compounds except RX-P770, which had a modal MIC of 4 g/ml. RX-P763, RX-P766, RX-P792, RX-P793, and RX-P808 had similar MIC distributions, while RX-P770 seemed to be 1 dilution less potent than its fellow novel compounds, as illustrated in Fig. 2 . Marketed compounds tended to have higher modal MICs (in g/ ml, with ranges shown in parentheses): 16 (0.25 to Ն128) for imipenem, 32 (Յ0.5 to Ն128) for piperacillin-tazobactam, 32 (1 to Ն128) for ceftazidime, 0.125 (Յ0.06 to Ն128) for ciprofloxacin, and 1 (0.25 to Ն128) for tobramycin. Imipenem and piperacillin-tazobactam had elevated MIC 50 and MIC 90 values of 4 and 32 and of 32 and 256 g/ml, respectively. Ceftazidime MIC 50 and MIC 90 values were 16 and 128 g/ml, respectively. The final two marketed compounds, ciprofloxacin and tobramycin, had MIC 50 and MIC 90 values of 0.5 and 1 and of 16 and 128 g/ml, respectively. The MIC distributions of each resistant phenotype are shown in Table 1 . The MIC profile of the six novel compounds did not change when R-IMI was broken out, with the exception of the RX-P763 MIC 50 , which increased by one dilution to 4 g/ml. None of the novel compounds' MIC profiles changed based on R-TAZ isolates, while the potency of ceftazidime decreased by approximately 2 dilutions. Similar results were seen for all agents against R-CIPRO isolates. MIC 50 and MIC 90 values for the novel compounds changed by Յ1 dilution, while the MIC 50 for ciprofloxacin increased by 5 dilutions and the MIC 90 increased by 1 dilution, to 16 and 32 g/ml, respectively. After separating those isolates that were multidrug resistant, the MIC 50 values for RX-P763 and RX-P792 changed by 1-fold dilutions from 2 to 4 g/ml, while the other four compounds did not show any changes in MIC profiles. Of note, six isolates contributed to all of the MICs that were Ն16 g/ml for the novel compounds. The isolates were collected from geographically diverse locations (two isolates from Ohio and one each from Alabama, the District of Columbia, Georgia, and Florida), were generally not MDR, and were obtained from different sites of infection. Of these six isolates, three were R-IMI, three were R-TAZ, four were R-TZP, one was R-TOBRA, and two were R-CIPRO. The modal MICs for each of the compounds against these six isolates were 4 g/ml for RX-P793 (range, 4 to 16 g/ml), 8 g/ml for RX-P766 (range, 4 to 16 g/ ml) and RX-P808 (range, 4 to 16 g/ml), and 16 g/ml for RX-P763 (range, 4 to 32 g/ml), RX-P770 (range, 8 to 16 g/ml), and RX-P792 (range, 4 to 64 g/ml).
Respiratory isolates (n ϭ 111) were separated, and three novel compounds, RX-P766, RX-P770, and RX-P793, were compared against this cache of isolates (8) . The MIC distributions of the novel compounds were very similar to the whole collection of 200 isolates. When broken out according to those isolates collected in the ward and those collected in the ICU, there were no changes to the MIC distributions of the three compounds (data not shown). Further, the 3 compounds demonstrated greater potencies in vitro than currently utilized antimicrobials for P. aeruginosa respiratory infections.
Overall, these data showed that all six novel compounds demonstrated in vitro activity against a collection of highly resistant P. aeruginosa isolates. All of the novel compounds demonstrated a unimodal MIC distribution with this collection of isolates. However, elevated MICs were observed. These six isolates (3%) contributed to all of the observed MICs that were Ն16 g/ml, suggesting some type of cross-resistance between the novel compounds. While the genetic profiles of these isolates have not been elucidated and the resistance mechanism(s) has not been identified, it is suspected that multiple resistance mechanisms, possibly including efflux pumps, are involved, given the differing resistance phenotypes (2) . With a new mechanism of action and these in vitro data, these novel compounds could provide new options for clinicians against multidrug-resistant P. aeruginosa.
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